Thermo Fisher Scientific Inc. TMO
At closeNov 4, 2026, 7:59 AM EST
Pre-market · Nov 4, 7:59 AM ET
- YTD
- +20.52%
- 1 year
- +23.55%
- Market cap
- 258.75B
- Revenue (ttm)
- 47.35B
- Profit margin
- 14.94%
- EPS (ttm)
- 18.96
- Shares out
- 370.52M
- P/E ratio
- 36.83
- Forward P/E
- 25.14
- Dividend
- 1.88 (0.27%)
- Ex-dividend date
- Sep 14, 2026
- YTD return
- +20.52%
- 1-year return
- +23.55%
- Volume
- 1.63M
- Avg volume
- 2.09M
- Open
- 677.92
- Previous close
- 682.65
- Day's range
- 672.00 – 700.19
- 52-week range
- 435.27 – 711.85
- Beta
- 0.84
- Analysts
- Strong Buy
- Price target
- 752.12 (+7.7%)
- Earnings date
- Feb 4, 2027
2Y +142.87 (+25.72%)
Key statistics
- Enterprise value
- 288.38B
- PEG ratio
- 1.99
- Price / sales
- 5.46
- Price / book
- 4.73
- Dividend yield
- 0.28%
- Payout ratio
- 9.70%
- Revenue growth
- 9.10%
- Free cash flow
- 6.44B
- Total cash
- 6.06B
- Total debt
- 41.37B
- Return on equity
- 13.38%
- Short % of float
- 1.32%
- 50-day average
- 655.71
- 200-day average
- 551.66
Analyst view
Consensus: strong buy
- Target (low)
- 590.00
- Target (mean)
- 752.12
- Target (high)
- 830.00
- Strong buy3
- Buy20
- Hold3
- Sell0
- Strong sell1
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 7.13.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 26, 2026 | 7.13 | — | — | — |
| Oct 21, 2026 | Sep 26, 2026 | 6.40 | 6.68 | +0.28 | +4.37% |
| Jul 23, 2026 | Jun 27, 2026 | 5.72 | 6.03 | +0.31 | +5.42% |
| Apr 23, 2026 | Mar 28, 2026 | 5.25 | 5.44 | +0.19 | +3.62% |
| Jan 29, 2026 | Dec 31, 2025 | 6.45 | 6.57 | +0.12 | +1.86% |
| Oct 22, 2025 | Sep 27, 2025 | 5.50 | 5.79 | +0.29 | +5.27% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Argus Research | main | Buy | Buy |
| Oct 23, 2026 | Citigroup | main | Buy | Buy |
| Oct 22, 2026 | Barclays | main | Overweight | Overweight |
| Oct 22, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 22, 2026 | TD Cowen | main | Buy | Buy |
| Oct 22, 2026 | Stifel | main | Buy | Buy |
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- thermofisher.com
News
Thermo Fisher Scientific Inc. $TMO Stock: BOCHK Asset Management Ltd Lowers Position 
$100 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth This Much Today 
Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet 
Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet 
Argus Research Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $780 
Citigroup Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $800 
Long-Awaited Qiagen Buyout Closes At 15x EBITDA Multiple as Slow Growth Curbs Pricing 
Barclays Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $775 
RBC Capital Maintains Sector Perform on Thermo Fisher Scientific, Raises Price Target to $730 - TD Cowen Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $810
Your note
Sign in to keep a note on TMO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOXER MICHAEL A | General Counsel | Sale | Mar 9, 2025 | 10,815 |
| BRITT LISA P | Officer | Sale | Aug 18, 2026 | 14,784 |
| CASPER MARC N | Chief Executive Officer | Sale | Aug 23, 2026 | 140,225 |
| CHAI NELSON J | Director | Stock Award(Grant) | May 19, 2026 | 15,316 |
| LAGARDE MICHEL | Chief Operating Officer | Stock Award(Grant) | Feb 24, 2026 | 86,347 |
| LOWERY FREDERICK M. | Officer | Stock Award(Grant) | Feb 24, 2026 | 17,133 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.35% | 30,919,632 | 21.59B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.55% | 24,276,316 | 16.95B | Jun 29, 2026 |
| State Street Corporation | 4.54% | 16,825,879 | 11.75B | Jun 29, 2026 |
| FMR, LLC | 3.80% | 14,084,488 | 9.84B | Jun 29, 2026 |
| Morgan Stanley | 2.90% | 10,763,066 | 7.52B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 2.30% | 8,503,527 | 5.94B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 11,797,800 | 8.24B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.60% | 9,628,713 | 6.72B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 4,926,507 | 3.44B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 4,823,975 | 3.37B | Aug 30, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.23% | 4,572,555 | 3.19B | Sep 29, 2026 |
| Fidelity Contrafund | 1.11% | 4,123,966 | 2.88B | Aug 30, 2026 |